| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | PHA-665752 | CCLE | pan-cancer | AAC | -0.058 | 0.2 |
| mRNA | crizotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | Lisitinib | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | CGP-60474 | GDSC1000 | pan-cancer | AAC | 0.062 | 0.2 |
| mRNA | BRD-K02492147 | CTRPv2 | pan-cancer | AAC | -0.049 | 0.2 |
| mRNA | AMG-706 | GDSC1000 | pan-cancer | AAC | -0.042 | 0.2 |
| mRNA | Cisplatin | GDSC1000 | pan-cancer | AAC | -0.041 | 0.2 |
| mRNA | LBW242 | CCLE | pan-cancer | AAC | -0.057 | 0.2 |
| mRNA | 17-AAG | CCLE | pan-cancer | AAC | -0.056 | 0.2 |
| mRNA | CIL56 | CTRPv2 | pan-cancer | AAC | 0.055 | 0.2 |